NIH VideoCast - NIH Research Festival Plenary Session III - Cell-based immune therapies

Skip Navigation

NIH Research Festival Plenary Session III - Cell-based immune therapies

Loading... Loading video...

417 Views

Air date:	Friday, September 16, 2016, 10:00:00 AM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 417 (88 Live, 329 On-demand)
Category:	Conferences
Runtime:	02:01:23
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	Cell-based immune therapies, such as immunotherapy for cancer, are among the hottest topics in clinical research. A centuries-old concept of stimulating the immune system to fight a non-infectious disease, immunotherapy became a viable treatment that doctors could exert some degree of control over as a result of pioneering research at the NCI in the 1960s and 1970s on monoclonal antibodies (Michael Potter) and Interleukin-2 (Robert Gallo). Building on such advances, NCI’s Steven Rosenberg, M.D., Ph.D. was the first to recognize the potential of Il-2 and apply it as a novel anti-cancer agent, in 1984. Rosenberg has spent most of his 40-year-career at the NIH improving various techniques, most recently developing chimeric antigen receptor therapy and T cell receptor gene-engineered cell therapy to fine-tune and turbo-charge the killing of cancer cells. Rosenberg’s body of research has given rise to numerous methods to harness the immune system to fight cancer and other chronic, non-infectious diseases. And many of Rosenberg’s NIH colleagues are now at the forefront of these pursuits. This plenary session features Steve Rosenberg, providing an historical context that only he can best deliver, as well as an update on his latest clinical work. Nicholas Restifo, M.D. (NCI), will discuss new immunotherapies for patients with advanced cancer. And John Tisdale, M.D. (NHLBI), will present his research combining hematopoietic stem cell methods with immunotherapy for the treatment of the genetic-based sickle cell disease. For more information go to https://researchfestival.nih.gov/2016/plenary-sessions

NLM Title:	NIH Research Festival. Plenary session III, Cell-based immune therapies / Dr. Nicholas Restifo, Dr. Steven Rosenberg, and Dr. John Tisdale.
Author:	Restifo, Nicholas P. Rosenberg, Steven A. Tisdale, John F. NIH Research Festival National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): Cell-based immune therapies, such as immunotherapy for cancer, are among the hottest topics in clinical research. A centuries-old concept of stimulating the immune system to fight a non-infectious disease, immunotherapy became a viable treatment that doctors could exert some degree of control over as a result of pioneering research at the NCI in the 1960s and 1970s on monoclonal antibodies (Michael Potter) and Interleukin-2 (Robert Gallo). Building on such advances, NCI's Steven Rosenberg, M.D., Ph.D. was the first to recognize the potential of Il-2 and apply it as a novel anti-cancer agent, in 1984. Rosenberg has spent most of his 40-year-career at the NIH improving various techniques, most recently developing chimeric antigen receptor therapy and T cell receptor gene-engineered cell therapy to fine-tune and turbo-charge the killing of cancer cells. Rosenberg's body of research has given rise to numerous methods to harness the immune system to fight cancer and other chronic, non-infectious diseases. And many of Rosenberg's NIH colleagues are now at the forefront of these pursuits. This plenary session features Steve Rosenberg, providing an historical context that only he can best deliver, as well as an update on his latest clinical work. Nicholas Restifo, M.D. (NCI), will discuss new immunotherapies for patients with advanced cancer. And John Tisdale, M.D. (NHLBI), will present his research combining hematopoietic stem cell methods with immunotherapy for the treatment of the genetic-based sickle cell disease.
Subjects:	Anemia, Sickle Cell--immunology Anemia, Sickle Cell--therapy Hematopoietic Stem Cell Transplantation Neoplasms--immunology Neoplasms--therapy Precision Medicine
Publication Types:	Congress Webcast

NLM Classification:	QZ 266
NLM ID:	101693825
CIT Live ID:	19906
Permanent link:	https://videocast.nih.gov/watch=19906

Related Videos...